RNAC — Cartesian Therapeutics Share News
0.000.00%
Last trade - 00:00- $186.98m
- $92.22m
- $2.80m
Selecta Biosciences Inc expected to post a loss of 8 cents a share - Earnings Preview
Selecta Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Selecta Biosciences Reports First Quarter 2023 Financial Results
Selecta Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Selecta Biosciences Inc - On March 31, Co Entered Into Fourth Amendment To Loan And Security Agreement
U.S. STOCKS ON THE MOVE-Nike, Nvidia, Boeing
H.C. Wainwright says regulatory approval for Selecta Bio's gout therapy likely
U.S. RESEARCH ROUNDUP-Adobe, Nike, Roper Technologies
U.S. STOCKS ON THE MOVE-CVRx, Tesla, So-Young International
U.S. STOCKS ON THE MOVE-Knight-Swift, BioNTech, US regional banks
Selecta Bio up as gout treatment meets main goals in late-stage trials
Brief: Selecta Biosciences Says Phase 3 Dissolve Program Of SEL-212 In Chronic Refractory Gout Meets Primary Endpoint
Selecta Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Selecta Biosciences Reports Fourth Quarter And Full Year 2022 Financial Results
Selecta Biosciences rises on licensing deal for genetic disorder drug
Brief: Selecta Biosciences Provides Business Update And Outlook For 2023
Brief: Selecta Biosciences And Astellas Pharma Inc Announce Exclusive Licensing And Development Agreement For Xork Igg Protease
Brief: Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection For IgA Nephropathy Program
Selecta Biosciences Inc reports results for the quarter ended in September - Earnings Summary